Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis
Abstract
1. Introduction
2. Materials and Methods
2.1. Setting
2.2. Quality of Life Questionnaires
2.3. Further Parameters of Interest
2.4. Statistics
3. Results
4. Discussion
4.1. Limitations
4.2. Future Research
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ATTR | amyloid transthyretin |
ATTR-CM | amyloid transthyretin cardiomyopathy |
CA | cardiac amyloidosis |
COMPASS-31 | Composite Autonomic Symptom Score-31 |
eGFR | estimated glomerular filtration rate |
HbA1c | glycated hemoglobin |
HF | heart failure |
IQR | interquartile range |
KCCQ | Kansas City Cardiomyopathy Questionnaire |
NAC | National Amyloidosis Centre |
NYHA | New York Heart Association functional class |
NT-proBNP | N-terminal prohormone of brain natriuretic peptide |
References
- Kittleson, M.M.; Maurer, M.S.; Ambardekar, A.V.; Bullock-Palmer, R.P.; Chang, P.P.; Eisen, H.J.; Nair, A.P.; Nativi-Nicolau, J.; Ruberg, F.L. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association. Circulation 2020, 144, E7–E22. [Google Scholar] [CrossRef] [PubMed]
- Grogan, M.; Scott, C.G.; Kyle, R.A.; Zeldenrust, S.R.; Gertz, M.A.; Lin, G.; Klarich, K.W.; Miller, W.L.; Maleszewski, J.J.; Dispenzieri, A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J. Am. Coll. Cardiol. 2016, 68, 1014–1020. [Google Scholar] [CrossRef] [PubMed]
- Aurich, M.; Bucur, J.; Vey, J.A.; Greiner, S.; Aus Dem Siepen, F.; Hegenbart, U.; Schönland, S.; Katus, H.A.; Frey, N.; Mereles, D. Prognosis of Light Chain Amyloidosis: A Multivariable Analysis for Survival Prediction in Patients with Cardiac Involvement Proven by Endomyocardial Biopsy. Open Heart 2023, 10, e002310. [Google Scholar] [CrossRef] [PubMed]
- Sanchorawala, V. Systemic Light Chain Amyloidosis. N. Engl. J. Med. 2024, 390, 2295–2307. [Google Scholar] [CrossRef]
- Damy, T.; Costes, B.; Hagège, A.A.; Donal, E.; Eicher, J.C.; Slama, M.; Guellich, A.; Rappeneau, S.; Gueffet, J.P.; Logeart, D.; et al. Prevalence and Clinical Phenotype of Hereditary Transthyretin Amyloid Cardiomyopathy in Patients with Increased Left Ventricular Wall Thickness. Eur. Heart J. 2016, 37, 1826–1834. [Google Scholar] [CrossRef]
- Poledniczek, M.; Kronberger, C.; Willixhofer, R.; Ermolaev, N.; Cherouny, B.; Dachs, T.-M.; Rettl, R.; Binder-Rodriguez, C.; Camuz Ligios, L.; Gregshammer, B.; et al. Health-Related Quality of Life Is an Independent Predictor of Mortality and Hospitalisations in Transthyretin Amyloid Cardiomyopathy: A Prospective Cohort Study. Qual. Life Res. 2024, 33, 2743–2753. [Google Scholar] [CrossRef]
- Clerc, O.F.; Vijayakumar, S.; Cuddy, S.A.M.; Bianchi, G.; Canseco Neri, J.; Taylor, A.; Benz, D.C.; Datar, Y.; Kijewski, M.F.; Yee, A.J.; et al. Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes. JACC Heart Fail. 2024, 12, 1994–2006. [Google Scholar] [CrossRef]
- Poli, L.; Labella, B.; Cotti Piccinelli, S.; Caria, F.; Risi, B.; Damioli, S.; Padovani, A.; Filosto, M. Hereditary Transthyretin Amyloidosis: A Comprehensive Review with a Focus on Peripheral Neuropathy. Front. Neurol. 2023, 14, 1242815. [Google Scholar] [CrossRef]
- Louwsma, J.; Brunger, A.F.; Bijzet, J.; Kroesen, B.J.; Roeloffzen, W.W.H.; Bischof, A.; Kuhle, J.; Drost, G.; Lange, F.; Kuks, J.B.M.; et al. Neurofilament Light Chain, a Biomarker for Polyneuropathy in Systemic Amyloidosis. Amyloid 2021, 28, 50–55. [Google Scholar] [CrossRef]
- Arbelo, E.; Protonotarios, A.; Gimeno, J.R.; Arbustini, E.; Barriales-Villa, R.; Basso, C.; Bezzina, C.R.; Biagini, E.; Blom, N.A.; de Boer, R.A.; et al. 2023 ESC Guidelines for the Management of Cardiomyopathies Developed by the Task Force on the Management of Cardiomyopathies of the European Society of Cardiology (ESC). Eur. Heart J. 2023, 44, 3503–3626. [Google Scholar] [CrossRef]
- Sletten, D.M.; Suarez, G.A.; Low, P.A.; Mandrekar, J.; Singer, W. COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom Score. Mayo Clin. Proc. 2012, 87, 1196–1201. [Google Scholar] [CrossRef] [PubMed]
- Meling, S.; Tjora, E.; Eichele, H.; Ejskjaer, N.; Carlsen, S.; Njølstad, P.R.; Brock, C.; Søfteland, E. The Composite Autonomic Symptom Score 31 Questionnaire: A Sensitive Test to Detect Risk for Autonomic Neuropathy. J. Diabetes Res. 2023, 2023, 4441115. [Google Scholar] [CrossRef] [PubMed]
- Green, C.P.; Porter, C.B.; Bresnahan, D.R.; Spertus, J.A. Development and Evaluation of the Kansas City Cardiomyopathy Questionnaire: A New Health Status Measure for Heart Failure. J. Am. Coll. Cardiol. 2000, 35, 1245–1255. [Google Scholar] [CrossRef] [PubMed]
- Ravera, A.; Santema, B.T.; Sama, I.E.; Meyer, S.; Lombardi, C.M.; Carubelli, V.; Ferreira, J.P.; Lang, C.C.; Dickstein, K.; Anker, S.D.; et al. Quality of Life in Men and Women with Heart Failure: Association with Outcome, and Comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 Dimensions Questionnaire. Eur. J. Heart Fail. 2021, 23, 567–577. [Google Scholar] [CrossRef]
- Greene, S.J.; Butler, J.; Spertus, J.A.; Hellkamp, A.S.; Vaduganathan, M.; Devore, A.D.; Albert, N.M.; Duffy, C.I.; Patterson, J.H.; Thomas, L.; et al. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021, 6, 522–531. [Google Scholar] [CrossRef]
- Spertus, J.A.; Jones, P.G. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. Circ. Cardiovasc. Qual. Outcomes 2015, 8, 469–476. [Google Scholar] [CrossRef]
- Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.; Castro, A.F.; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Lente, F.V.; Greene, T.; et al. A New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 2009, 150, 604. [Google Scholar] [CrossRef]
- Gillmore, J.D.; Damy, T.; Fontana, M.; Hutchinson, M.; Lachmann, H.J.; Martinez-Naharro, A.; Quarta, C.C.; Rezk, T.; Whelan, C.J.; Gonzalez-Lopez, E.; et al. A New Staging System for Cardiac Transthyretin Amyloidosis. Eur. Heart J. 2018, 39, 2799–2806. [Google Scholar] [CrossRef]
- Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, D.E.; Hansen, T.B.; et al. 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD. Eur. Heart J. 2020, 41, 255–323. [Google Scholar] [CrossRef]
- Yamada, S.; Yoshihisa, A.; Hijioka, N.; Kamioka, M.; Kaneshiro, T.; Yokokawa, T.; Misaka, T.; Ishida, T.; Takeishi, Y. Autonomic Dysfunction in Cardiac Amyloidosis Assessed by Heart Rate Variability and Heart Rate Turbulence. Ann. Noninvasive Electrocardiol. 2020, 25, e12749. [Google Scholar] [CrossRef]
- Kharoubi, M.; Roche, F.; Bézard, M.; Hupin, D.; Silva, S.; Oghina, S.; Chalard, C.; Zaroui, A.; Galat, A.; Guendouz, S.; et al. Prevalence and Prognostic Value of Autonomic Neuropathy Assessed by Sudoscan® in Transthyretin Wild-type Cardiac Amyloidosis. ESC Heart Fail. 2020, 8, 1656. [Google Scholar] [CrossRef] [PubMed]
- Bukhari, S.; Oliveros, E.; Parekh, H.; Farmakis, D. Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis. Curr. Probl. Cardiol. 2023, 48, 101571. [Google Scholar] [CrossRef] [PubMed]
- Ruberg, F.L.; Grogan, M.; Hanna, M.; Kelly, J.W.; Maurer, M.S. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019, 73, 2872–2891. [Google Scholar] [CrossRef] [PubMed]
- Koike, H.; Katsuno, M. The Ultrastructure of Tissue Damage by Amyloid Fibrils. Molecules 2021, 26, 4611. [Google Scholar] [CrossRef]
- Papagianni, A.; Ihne, S.; Zeller, D.; Morbach, C.; Üçeyler, N.; Sommer, C. Clinical and Apparative Investigation of Large and Small Nerve Fiber Impairment in Mixed Cohort of ATTR-Amyloidosis: Impact on Patient Management and New Insights in Wild-Type. Amyloid 2022, 29, 14–22. [Google Scholar] [CrossRef]
- Singh, R.; Arbaz, M.; Rai, N.K.; Joshi, R. Diagnostic Accuracy of Composite Autonomic Symptom Scale 31 (COMPASS-31) in Early Detection of Autonomic Dysfunction in Type 2 Diabetes Mellitus. Diabetes Metab. Syndr. Obes. 2019, 12, 1735–1742. [Google Scholar] [CrossRef]
- Pearson, M.J.; Smart, N.A. Exercise Therapy and Autonomic Function in Heart Failure Patients: A Systematic Review and Meta-Analysis. Heart Fail. Rev. 2018, 23, 91–108. [Google Scholar] [CrossRef]
Variable | Total | COMPASS-31 Score > Median | COMPASS-31 Score ≤ Median | p-Value |
---|---|---|---|---|
n = 129 | n = 62 | n = 67 | ||
Patient demographics | ||||
Age (years), median (IQR) | 81.7 (77.4–84.3) | 82.8 (79.3–84.6) | 81.1 (76.1–83.6) | 0.100 |
Female sex, n (%) | 21 (16.3%) | 13 (21.0%) | 8 (11.9%) | 0.165 |
ATTRv, n (%) | 10 (7.8%) | 5 (7.5%) | 5 (8.2%) | 0.877 |
AL, n (%) | 3 (2.3%) | 1 (1.6%) | 2 (3.0%) | 0.627 |
Clinical parameters and laboratory evaluations | ||||
BMI, kg/m2, median (IQR) | 25.3 (22.5–27.5) | 23.9 (21.6–27.4) | 25.8 (23.6–27.6) | 0.082 |
NT-proBNP, pg/mL, median (IQR) | 2091 (864–3695) | 2325 (846–4866) | 1820 (928–3327) | 0.234 |
Troponin T, ng/L, median (IQR) | 44.0 (30.0–70.0) | 47.5 (32.5–73.2) | 42.0 (27.0–58.5) | 0.139 |
Creatinine, mg/dL, median (IQR) | 1.2 (1.0–1.5) | 1.2 (1.0–1.6) | 1.2 (1.0–1.4) | 0.531 |
eGFR, ml/min/1.73 m2, mean ± SD | 53.6 ± 19.7 | 51.5 ± 21.5 | 55.5 ± 17.8 | 0.247 |
HbA1c, %, median (IQR) | 5.8 (5.5–6.2) | 5.8 (5.5–6.3) | 5.7 (5.5–6.2) | |
NYHA stage, n (%) | 0.001 | |||
1 | 31 (24.0%) | 6 (9.7%) | 25 (37.3%) | |
2 | 57 (44.2%) | 30 (48.4%) | 27 (40.3%) | |
3 | 41 (31.8%) | 26 (41.9%) | 15 (22.4%) | |
NAC stage, n (%) | 0.101 | |||
1 | 64 (50.0%) | 28 (45.2%) | 36 (54.5%) | |
2 | 36 (28.1%) | 16 (25.8%) | 20 (30.3%) | |
3 | 28 (21.9%) | 18 (29.0%) | 10 (15.2%) | |
Medical history | ||||
Significant coronary artery disease, n (%) | 27 (20.9%) | 11 (17.7%) | 16 (23.9%) | 0.392 |
Atrial fibrillation, n (%) | 85 (65.9%) | 43 (69.4%) | 42 (62.7%) | 0.425 |
Atrial flutter, n (%) | 8 (6.2%) | 4 (6.5%) | 4 (6.0%) | 0.910 |
Diabetes mellitus, n (%) | 27 (20.9%) | 12 (19.4%) | 15 (22.4%) | 0.672 |
Arterial hypertension, n (%) | 88 (68.2%) | 44 (71.0%) | 44 (65.7%) | 0.519 |
Medical therapy | ||||
Disease-modifying therapy, n (%) | 88 (68.2%) | 40 (64.5%) | 48 (71.6%) | 0.385 |
Disease-modifying therapy ≥ 6 months, n (%) | 79 (61.2%) | 36 (58.1%) | 43 (64.2%) | 0.476 |
SGLT2i, n (%) | 58 (45.0%) | 32 (51.6%) | 26 (38.8%) | 0.228 |
MRA, n (%) | 57 (44.2%) | 28 (45.2%) | 29 (43.3%) | 0.830 |
Loop diuretics, n (%) | 78 (60.5%) | 41 (66.1%) | 37 (55.2%) | 0.206 |
Loop diuretic dose, mg/kg, median (IQR) | 0.24 (0.00–0.61) | 0.30 (0.00–0.67) | 0.19 (0.00–0.51) | 0.056 |
Questionnaire scores | ||||
COMPASS-31 score, median (IQR) | 14 (6–29) | 31 (19–38) | 7 (3–9) | <0.001 |
Score > cut-off, n (%) | 75 (58.1%) | 62 (100%) | 13 (19.4%) | <0.001 |
Orthostatic intolerance, median (IQR) | 0 (0–16) | 16 (9–23) | 0 (0–0) | <0.001 |
Any orthostatic intolerance, n (%) | 55 (42.6%) | 49 (79.0%) | 6 (9.0%) | <0.001 |
Vasomotor dysfunction, median (IQR) | 0 (0–0) | 0 (0–2) | 0 (0–0) | 0.002 |
Any vasomotor dysfunction, n (%) | 29 (22.5%) | 21 (33.9%) | 8 (11.9%) | 0.003 |
Secretomotor dysfunction, median (IQR) | 2 (0–6) | 6 (2–6) | 0 (0–2) | <0.001 |
Any secretomotor dysfunction, n (%) | 77 (59.7%) | 53 (85.5%) | 24 (35.8%) | <0.001 |
Gastrointestinal dysfunction, median (IQR) | 4 (1–7) | 6 (4–10) | 2 (1–4) | <0.001 |
Any gastrointestinal dysfunction, n (%) | 113 (87.6%) | 61 (98.4%) | 52 (77.6%) | <0.001 |
Bladder dysfunction, median (IQR) | 1 (0–2) | 2 (1–3) | 0 (0–1) | <0.001 |
Any bladder dysfunction, n (%) | 79 (61.2%) | 48 (77.4%) | 31 (46.3%) | <0.001 |
Pupillomotor dysfunction, median (IQR) | 1 (0–2) | 2 (1–2) | 0 (0–1) | <0.001 |
Any pupillomotor dysfunction, n (%) | 87 (67.4%) | 52 (83.9%) | 35 (52.2%) | <0.001 |
KCCQ, median (IQR) | 66 (48–82) | 54 (43–65) | 80 (64–90) | <0.001 |
Physical limitations, median (IQR) | 67 (50–83) | 60 (39–81) | 75 (58–83) | 0.004 |
Symptom frequency, median (IQR) | 75 (67–83) | 58 (45–77) | 85 (67–92) | <0.001 |
Quality of life, median (IQR) | 75 (52–88) | 50 (38–66) | 75 (62–88) | <0.001 |
Social limitations, median (IQR) | 67 (33–84) | 50 (33–67) | 75 (58–94) | <0.001 |
Variable | Total | ATTRwt | ATTRv | p-Value |
---|---|---|---|---|
n = 129 | n = 118 | n = 10 | ||
Patient demographics | ||||
Age (years), median (IQR) | 81.7 (77.4–84.3) | 81.9 (78.6–84.3) | 68.6 (64.5–78.5) | 0.003 |
Female sex, n (%) | 21 (16.3%) | 17 (14.4%) | 4 (40.0%) | 0.036 |
AL, n (%) | 3 (2.3%) | 3 (2.5%) | 0 (0.0%) | <0.001 |
Clinical parameters and laboratory evaluations | ||||
BMI, kg/m2, median (IQR) | 25.3 (22.5–27.5) | 25.2 (22.8–27.5) | 25.6 (20.2–28.8) | 0.947 |
NT-proBNP, pg/mL, median (IQR) | 2091 (864–3695) | 2083 (920–3773) | 2452 (884–3406) | 0.996 |
Troponin T, ng/L, median (IQR) | 44.0 (30.0–70.0) | 43.0 (30.0–70.0) | 54.0 (24.0–57.0) | 0.732 |
Creatinine, mg/dL, median (IQR) | 1.2 (1.0–1.5) | 1.3 (1.0–1.5) | 1.1 (0.8–1.7) | 0.236 |
eGFR, ml/min/1.73 m2, mean ± SD | 53.6 ± 19.7 | 52.7 ± 18.9 | 61.3 ± 26.8 | 0.341 |
HbA1c, %, median (IQR) | 5.8 (5.5–6.2) | 5.8 (5.5–6.2) | 5.9 (5.6–6.3) | 0.399 |
NYHA stage, n (%) | 0.592 | |||
1 | 31 (24.0%) | 30 (25.4%) | 1 (10.0%) | |
2 | 57 (44.2%) | 50 (42.4%) | 6 (60.0%) | |
3 | 41 (31.8%) | 38 (32.2%) | 3 (30.0%) | |
NAC stage, n (%) | 0.757 | |||
1 | 64 (50.0%) | 58 (49.6%) | 5 (50.0%) | |
2 | 36 (28.1%) | 34 (29.1%) | 2 (20.0%) | |
3 | 28 (21.9%) | 25 (21.4%) | 3 (30.0%) | |
Questionnaire scores | ||||
COMPASS-31 score, median (IQR) | 14 (6–29) | 14 (6–27) | 14 (6–35) | 0.606 |
Score > cut-off, n (%) | 75 (58.1%) | 69 (58.5%) | 5 (50.0%) | 0.602 |
Orthostatic intolerance, median (IQR) | 0 (0–16) | 0 (0–16) | 0 (0–16) | 0.870 |
Any orthostatic intolerance, n (%) | 55 (42.6%) | 50 (42.4%) | 4 (40.0%) | 0.884 |
Vasomotor dysfunction, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–2) | 0.165 |
Any vasomotor dysfunction, n (%) | 29 (22.5%) | 24 (20.3%) | 4 (40.0%) | 0.149 |
Secretomotor dysfunction, median (IQR) | 2 (0–6) | 2 (0–6) | 2 (0–6) | 0.989 |
Any secretomotor dysfunction, n (%) | 77 (59.7%) | 71 (60.2%) | 5 (50.0%) | 0.530 |
Gastrointestinal dysfunction, median (IQR) | 4 (1–7) | 4 (1–6) | 6 (4–8) | 0.142 |
Any gastrointestinal dysfunction, n (%) | 113 (87.6%) | 103 (87.3%) | 9 (90.0%) | 0.803 |
Bladder dysfunction, median (IQR) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.930 |
Any bladder dysfunction, n (%) | 79 (61.2%) | 73 (61.9%) | 69 (60.0%) | 0.907 |
Pupillomotor dysfunction, median (IQR) | 1 (0–2) | 1 (0–2) | 2 (0–2) | 0.313 |
Any pupillomotor dysfunction, n (%) | 87 (67.4%) | 79 (66.9%) | 7 (70.0%) | 0.844 |
KCCQ, median (IQR) | 66 (48–82) | 65 (48–82) | 77 (59–87) | 0.492 |
Physical limitations, median (IQR) | 67 (50–83) | 67 (50–83) | 75 (60–81) | 0.839 |
Symptom frequency, median (IQR) | 75 (67–83) | 73 (52–88) | 83 (59–89) | 0.687 |
Quality of life, median (IQR) | 75 (52–88) | 62 (50–88) | 75 (53–88) | 0.475 |
Social limitations, median (IQR) | 67 (33–84) | 67 (33–83) | 79 (52–92) | 0.472 |
Variable | Orthostatic Intolerance Score | Vasomotor Score | Secretomotor Score | Gastrointestinal Score | Bladder Dysfunction Score | Pupillomotor Dysfunction | Overall Score | |
---|---|---|---|---|---|---|---|---|
Vasomotor score | Correlation | 0.12 | ||||||
p-value | 0.527 | |||||||
Secretomotor score | Correlation | 0.45 | 0.24 | |||||
p-value | <0.001 | 0.072 | ||||||
Gastrointestinal score | Correlation | 0.32 | 0.30 | 0.39 | ||||
p-value | 0.005 | 0.009 | <0.001 | |||||
Bladder dysfunction score | Correlation | 0.15 | 0.31 | 0.39 | 0.41 | |||
p-value | 0.438 | 0.007 | <0.001 | <0.001 | ||||
Pupillomotor score | Correlation | 0.35 | 0.15 | 0.37 | 0.31 | 0.29 | ||
p-value | 0.002 | 0.438 | 0.001 | 0.008 | 0.013 | |||
Overall Score | Correlation | 0.84 | 0.31 | 0.71 | 0.65 | 0.44 | 0.50 | |
p-value | <0.001 | 0.007 | <0.001 | <0.001 | <0.001 | <0.001 | ||
KCCQ physical limitations score | Correlation | −0.27 | −0.29 | −0.32 | −0.30 | −0.33 | −0.09 | −0.39 |
p-value | 0.029 | 0.016 | 0.006 | 0.011 | 0.006 | 0.635 | <0.001 | |
KCCQ symptom frequency score | Correlation | −0.32 | −0.30 | −0.48 | −0.46 | −0.44 | −0.21 | −0.54 |
p-value | 0.006 | 0.009 | <0.001 | <0.001 | <0.001 | 0.145 | <0.001 | |
KCCQ quality of life score | Correlation | −0.34 | −0.27 | −0.39 | −0.44 | −0.36 | −0.18 | −0.51 |
p-value | 0.004 | 0.029 | <0.001 | <0.001 | 0.002 | 0.305 | <0.001 | |
KCCQ social limitations score | Correlation | −0.35 | −0.23 | −0.37 | −0.36 | −0.35 | −0.08 | −0.48 |
p-value | 0.004 | 0.137 | 0.002 | 0.003 | 0.005 | 0.635 | <0.001 | |
KCCQ-12 Overall score | Correlation | −0.37 | −0.31 | −0.44 | −0.44 | −0.42 | −0.17 | −0.55 |
p-value | 0.001 | 0.008 | <0.001 | <0.001 | <0.001 | 0.322 | <0.001 |
Variable | Coef. | 95% CI | p-Value | Coef. | 95% CI | p-Value |
---|---|---|---|---|---|---|
Crude | Multivariate Adjustment | |||||
Age | 0.038 | −0.394–0.469 | 0.864 | |||
Female sex | 4.489 | −2.767–11.746 | 0.223 | |||
ATTRv | 3.786 | −6.293–13.866 | 0.459 | |||
NYHA | 6.712 | 3.282–10.142 | <0.001 | 0.316 | −3.507–4.139 | 0.870 |
NAC stage | 3.292 | −0.039–6.623 | 0.053 | |||
Diabetes mellitus | −2.353 | 8.964–4.258 | 0.483 | |||
Disease-modifying therapy ≥ 6 months | −3.733 | −9.225–1.759 | 0.181 | |||
KCCQ | −0.360 | −0.461–−0.260 | <0.001 | −0.356 | −0.481–−0.227 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Poledniczek, M.; Hölzl, K.; Kronberger, C.; Ermolaev, N.; Schmid, L.M.; Rettl, R.; Binder, C.; Camuz Ligios, L.; Eslami, M.; Hengstenberg, C.; et al. Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis. J. Clin. Med. 2025, 14, 4682. https://doi.org/10.3390/jcm14134682
Poledniczek M, Hölzl K, Kronberger C, Ermolaev N, Schmid LM, Rettl R, Binder C, Camuz Ligios L, Eslami M, Hengstenberg C, et al. Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis. Journal of Clinical Medicine. 2025; 14(13):4682. https://doi.org/10.3390/jcm14134682
Chicago/Turabian StylePoledniczek, Michael, Konstantin Hölzl, Christina Kronberger, Nikita Ermolaev, Lena Marie Schmid, René Rettl, Christina Binder, Luciana Camuz Ligios, Mahshid Eslami, Christian Hengstenberg, and et al. 2025. "Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis" Journal of Clinical Medicine 14, no. 13: 4682. https://doi.org/10.3390/jcm14134682
APA StylePoledniczek, M., Hölzl, K., Kronberger, C., Ermolaev, N., Schmid, L. M., Rettl, R., Binder, C., Camuz Ligios, L., Eslami, M., Hengstenberg, C., Badr Eslam, R., Bergler-Klein, J., Kastner, J., Kammerlander, A. A., & Duca, F. (2025). Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis. Journal of Clinical Medicine, 14(13), 4682. https://doi.org/10.3390/jcm14134682